Stomach Cancer Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiotherapy), Route Of Administration (Intravenous, Oral), Stage, Distribution Channel, End User - Global Forecast 2025-2032
Description
The Steroid Injections Market was valued at USD 5.28 billion in 2024 and is projected to grow to USD 5.72 billion in 2025, with a CAGR of 8.82%, reaching USD 10.39 billion by 2032.
A comprehensive orientation to steroid injection practice that links clinical rationale, administration pathways, and stakeholder priorities for strategic decision making
Steroid injections occupy a critical junction in contemporary musculoskeletal and inflammatory care, combining well-established pharmacology with evolving delivery practices and shifting regulatory expectations. Clinicians continue to rely on corticosteroid injections for targeted symptom relief in conditions ranging from osteoarthritis to bursitis, while manufacturers and service providers adapt to demand for improved formulations, safer delivery systems, and streamlined administration protocols. Market participants must interpret clinical guidelines, reimbursement pathways, and facility-level preferences in tandem to understand how therapeutic choices translate into procurement decisions and care pathways.
This introduction synthesizes the clinical rationale underpinning steroid injection use, highlights the operational considerations that influence site-of-care selection, and frames the commercial levers that inform product development and market access. By situating therapeutic practice within the broader context of payer priorities, patient expectations, and technological innovation, stakeholders can better anticipate where investment in clinical evidence, supply chain resilience, and stakeholder education will yield the greatest return. The subsequent sections expand on structural shifts, regulatory and policy influences, fine-grained segmentation, and actionable steps leaders can take to align portfolios with evolving needs across treatment settings and patient cohorts.
How clinical innovation, outpatient care migration, and heightened evidence expectations are collectively redefining the steroid injection landscape and commercial approaches
The landscape for steroid injections is undergoing transformative shifts driven by clinical, technological, and policy dynamics that are reshaping how therapies are developed, delivered, and reimbursed. Advances in formulation chemistry and delivery techniques have enabled more targeted duration of effect and improved local tolerability, prompting clinicians to reconsider product selection across indications such as arthritic pain and soft tissue inflammation. Simultaneously, the rise of value-based care models and clinician-administered outpatient procedures has accelerated migration toward ambulatory settings, creating demand for streamlined supply logistics and point-of-care inventory strategies.
Concurrently, stakeholder expectations around safety and evidence are tightening. Payers and procurement teams increasingly require robust, real-world effectiveness and safety data to support formulary placement and site-of-care incentives, which in turn motivates manufacturers to invest in post-market surveillance and pragmatic clinical trials. Interoperability of electronic health records and procedural documentation is improving the ability to measure outcomes tied to specific injection types and delivery settings, enabling more sophisticated cost-outcome analyses. Taken together, these vectors are shifting commercial emphasis from purely transactional selling toward integrated solutions that bundle product, education, and demonstrable clinical value.
Assessment of cumulative operational and strategic effects stemming from United States tariff measures enacted in 2025 that influence supply chains and procurement behavior
The introduction of tariffs and evolving trade policy frameworks in the United States in 2025 has had cumulative operational and strategic consequences for stakeholders engaged in the manufacture, distribution, and procurement of steroid injection products. Increased import duties on select pharmaceutical intermediates and device components have expanded landed costs and prompted procurement teams to reassess supplier geographies and contract structures. In response, manufacturers have accelerated supplier diversification, local sourcing strategies, and inventory buffer practices to protect continuity of care and maintain predictable pricing for institutional buyers.
Beyond immediate cost implications, the tariffs have catalyzed longer-term supply chain reconfiguration. Contract manufacturers and component suppliers outside tariff scopes have gained attention as firms seek to rebalance exposure. At the same time, regulatory compliance and paperwork have increased the administrative burden for cross-border shipments, influencing lead times and inventory planning at hospitals, ambulatory surgical centers, and clinics. Clinicians and administrators are adapting by privileging products with stable supply histories and by engaging in multi-year procurement arrangements that emphasize transparency on origin and contingency planning. These collective adjustments underline the importance of supply chain resilience and collaborative contracting as defensive strategies in an era of trade uncertainty.
An integrated segmentation framework linking molecule properties, treatment pathways, patient cohorts, clinical indications, care settings, and distribution channels for targeted strategy
High-resolution segmentation is central to meaningful strategy development because therapeutic choices and procurement dynamics vary significantly across molecule, delivery approach, patient demographics, indication, end user, and distribution channel. The product mix is differentiated by molecule type-Dexamethasone, Hydrocortisone, Methylprednisolone, and Triamcinolone-each bringing distinct potency, solubility, and duration profiles that shape clinician preference and formulation strategy. Treatment type stratification captures clinical workflow differences among joint injections, soft tissue injections, and spinal injections; within joint injections, clinical practice diverges between large joint and small joint protocols, while soft tissue procedures further split into bursa injections, ligament injections, and tendon injections, and spinal approaches bifurcate into epidural and intrathecal pathways, each with unique safety, training, and device requirements.
Patient type segmentation recognizes differing safety considerations, dosing regimens, and consent processes across adult, geriatric, and pediatric cohorts, necessitating tailored labeling, educational materials, and post-procedure monitoring protocols. Therapeutic indication breakdowns-encompassing back pain, bursitis, osteoarthritis, rheumatoid arthritis, and tendonitis-highlight how clinical guidelines and expected outcomes vary; back pain itself is parsed into lower back pain, sciatica, and upper back pain, each demanding specific injection approaches and diagnostic clarity. End-user segmentation distinguishes ambulatory surgical centers, clinics, and hospitals, with hospitals further divided into general and specialty institutions, influencing procurement scale, formularies, and in-house compounding capabilities. Distribution channel considerations separate hospital pharmacies, online pharmacies, and retail pharmacies, with retail further split into chain and independent pharmacies, affecting access, dispensing protocols, and patient counseling. Synthesizing these segmentation dimensions enables targeted clinical evidence generation, differentiated marketing, and operational planning that align products with the distinct needs of clinicians, payers, and patients across care settings.
A regional analysis of clinical adoption, regulatory expectations, and procurement mechanics across the Americas, Europe Middle East Africa, and Asia Pacific markets
Regional dynamics substantially influence clinical practice patterns, regulatory requirements, and procurement mechanisms, demanding regionally informed strategies for product registration, distribution, and stakeholder engagement. The Americas present diverse payer landscapes and a strong outpatient procedural shift that favors ambulatory surgical centers and clinic-based administration of injections, with established reimbursement pathways that reward efficiency and documented outcomes. Regulatory and reimbursement variability across national and subnational jurisdictions requires tailored evidence dossiers and adaptive pricing approaches to accommodate divergent procurement rules and hospital formulary processes.
The Europe, Middle East & Africa region displays heterogeneity in clinical adoption and infrastructure; Western European markets emphasize rigorous health technology assessment and long-term outcomes data, while several markets in the Middle East and Africa are focused on access, supply chain reliability, and capacity building for procedural training. These differences necessitate bifurcated strategies that combine robust clinical data packages with targeted capacity development. The Asia-Pacific region is characterized by rapid procedural uptake in ambulatory settings, strong local manufacturing capabilities in select markets, and varying regulatory regimes that influence ingredient sourcing and device approvals. Across all regions, successful entrants align their regulatory submissions, distribution partnerships, and clinician engagement programs with local practice conventions, reimbursement models, and supply chain realities.
Competitive and operational insights revealing how manufacturers, device innovators, and distribution partners are positioning for clinical adoption and supply resilience
Competitive dynamics in the steroid injection space are defined by a mix of pharmaceutical manufacturers, device innovators, contract manufacturing organizations, and specialty distributors that prioritize clinical evidence, supply reliability, and integrated service offerings. Leading manufacturers focus on optimizing formulation portfolios to address differentiated clinician needs for potency, onset, and duration while investing in safety and administration training programs that enhance product uptake in ambulatory and hospital settings. Device and delivery system innovators are introducing solutions that simplify procedure workflow, improve dosing precision, and reduce procedural risk, which in turn influence purchasing preferences among high-volume clinics and surgical centers.
Contract manufacturing and packaging partners are increasingly important as companies seek to localize production and manage cost pressures introduced by trade policy shifts. Distribution and logistics partners that demonstrate strong cold chain management, responsive replenishment, and transparent origin documentation provide competitive advantages, particularly for large healthcare systems and specialty hospitals. Across the competitive spectrum, companies that couple compelling clinical data with robust educational outreach and supply chain transparency stand to secure preferred placement on institutional formularies and long-term procurement agreements. Strategic partnerships that align manufacturing agility with clinical validation efforts will be critical for sustaining access and adoption in diverse end-user environments.
Practical and prioritized strategic actions for manufacturers and stakeholders to strengthen evidence, secure supply chains, and accelerate clinical adoption across diverse care settings
Industry leaders should pursue a coordinated agenda that blends clinical evidence generation, supply chain resilience, and targeted commercialization to capitalize on shifts in care delivery and payer expectations. Prioritize investment in pragmatic studies and real-world evidence that demonstrate comparative effectiveness across molecule types and treatment pathways, ensuring that dossiers address clinician questions around duration of benefit, safety in geriatric and pediatric populations, and outcomes across specific indications such as osteoarthritis, rheumatoid arthritis, and differentiated back pain subtypes. Align these evidence efforts with educational programs tailored to large joint versus small joint procedures and to specialized spinal techniques, thereby reducing adoption friction and building clinician confidence.
Simultaneously, strengthen supplier diversification and consider regionalized manufacturing partnerships to mitigate tariff exposure and reduce lead-time variability for hospitals, ambulatory surgical centers, and clinics. Enhance distribution strategies by forming deep collaborations with hospital pharmacies and specialty distributors, as well as by optimizing online pharmacy channel policies to support appropriate dispensing while maintaining adherence to regulatory requirements. Finally, implement segmented commercial strategies that reflect differences in end-user procurement behavior and distribution channel dynamics; for example, offer bundled training and inventory management solutions for ambulatory surgical centers, while delivering streamlined formulary submission packages and long-term supply guarantees for specialty hospitals. These combined actions will improve market responsiveness, protect margins, and accelerate adoption in priority clinical segments.
A rigorous mixed-methods methodology that integrates clinical literature review, procurement analysis, and primary stakeholder interviews for validated strategic insights
The research methodology underpinning this executive summary combines multi-source evidence gathering, primary stakeholder engagement, and cross-validation to ensure robustness and actionable insight. The approach begins with a comprehensive review of peer-reviewed clinical literature, clinical practice guidelines, and regulatory documentation to establish baseline evidence on molecule characteristics, procedural protocols, and safety considerations. This foundation is augmented by analyses of procurement guidelines, hospital formularies, and publicly available procedural utilization data to identify variations in site-of-care practice patterns and distribution channel behavior.
Primary research includes structured interviews with clinicians across specialties that administer injections, procurement leads from ambulatory surgical centers and hospitals, and supply chain managers responsible for pharmacy operations. These qualitative inputs are synthesized with secondary datasets and validated through triangulation techniques to reconcile conflicting observations and to surface consistent trends. Segmentation mapping and regional analyses are informed by coded interview data and cross-checked against regulatory frameworks and published clinical guidance. Throughout, emphasis was placed on methodological transparency, reproducibility of thematic findings, and the practical applicability of recommendations to support decision making by clinical, commercial, and supply chain stakeholders.
A forward-looking synthesis highlighting strategic priorities and the practical convergence of clinical evidence, supply resilience, and targeted commercialization in steroid injections
In conclusion, the steroid injection landscape is at an inflection point where clinical practice, payer expectations, and supply chain realities converge to create both risk and opportunity. Stakeholders who invest in differentiated clinical evidence, ensure supply chain diversification in response to trade and regulatory shifts, and tailor commercialization to segmented clinical and distribution pathways will be best positioned to secure sustainable adoption. The segmentation framework spanning molecule type, treatment modality, patient cohort, therapeutic indication, end user, and distribution channel provides a practical lens through which to prioritize investments and to design targeted market access strategies.
Looking ahead, the combination of enhanced delivery technologies, a growing emphasis on real-world outcomes, and regionally varied regulatory environments will continue to shape clinical adoption and procurement decisions. Organizations that proactively align their clinical development, manufacturing footprint, and commercial execution with these structural trends will reduce execution risk and create pathways to differentiated market presence. The recommendations outlined here offer a roadmap for translating analytical insight into measurable operational and commercial actions that support better patient outcomes and stronger institutional partnerships.
Note: PDF & Excel + Online Access - 1 Year
A comprehensive orientation to steroid injection practice that links clinical rationale, administration pathways, and stakeholder priorities for strategic decision making
Steroid injections occupy a critical junction in contemporary musculoskeletal and inflammatory care, combining well-established pharmacology with evolving delivery practices and shifting regulatory expectations. Clinicians continue to rely on corticosteroid injections for targeted symptom relief in conditions ranging from osteoarthritis to bursitis, while manufacturers and service providers adapt to demand for improved formulations, safer delivery systems, and streamlined administration protocols. Market participants must interpret clinical guidelines, reimbursement pathways, and facility-level preferences in tandem to understand how therapeutic choices translate into procurement decisions and care pathways.
This introduction synthesizes the clinical rationale underpinning steroid injection use, highlights the operational considerations that influence site-of-care selection, and frames the commercial levers that inform product development and market access. By situating therapeutic practice within the broader context of payer priorities, patient expectations, and technological innovation, stakeholders can better anticipate where investment in clinical evidence, supply chain resilience, and stakeholder education will yield the greatest return. The subsequent sections expand on structural shifts, regulatory and policy influences, fine-grained segmentation, and actionable steps leaders can take to align portfolios with evolving needs across treatment settings and patient cohorts.
How clinical innovation, outpatient care migration, and heightened evidence expectations are collectively redefining the steroid injection landscape and commercial approaches
The landscape for steroid injections is undergoing transformative shifts driven by clinical, technological, and policy dynamics that are reshaping how therapies are developed, delivered, and reimbursed. Advances in formulation chemistry and delivery techniques have enabled more targeted duration of effect and improved local tolerability, prompting clinicians to reconsider product selection across indications such as arthritic pain and soft tissue inflammation. Simultaneously, the rise of value-based care models and clinician-administered outpatient procedures has accelerated migration toward ambulatory settings, creating demand for streamlined supply logistics and point-of-care inventory strategies.
Concurrently, stakeholder expectations around safety and evidence are tightening. Payers and procurement teams increasingly require robust, real-world effectiveness and safety data to support formulary placement and site-of-care incentives, which in turn motivates manufacturers to invest in post-market surveillance and pragmatic clinical trials. Interoperability of electronic health records and procedural documentation is improving the ability to measure outcomes tied to specific injection types and delivery settings, enabling more sophisticated cost-outcome analyses. Taken together, these vectors are shifting commercial emphasis from purely transactional selling toward integrated solutions that bundle product, education, and demonstrable clinical value.
Assessment of cumulative operational and strategic effects stemming from United States tariff measures enacted in 2025 that influence supply chains and procurement behavior
The introduction of tariffs and evolving trade policy frameworks in the United States in 2025 has had cumulative operational and strategic consequences for stakeholders engaged in the manufacture, distribution, and procurement of steroid injection products. Increased import duties on select pharmaceutical intermediates and device components have expanded landed costs and prompted procurement teams to reassess supplier geographies and contract structures. In response, manufacturers have accelerated supplier diversification, local sourcing strategies, and inventory buffer practices to protect continuity of care and maintain predictable pricing for institutional buyers.
Beyond immediate cost implications, the tariffs have catalyzed longer-term supply chain reconfiguration. Contract manufacturers and component suppliers outside tariff scopes have gained attention as firms seek to rebalance exposure. At the same time, regulatory compliance and paperwork have increased the administrative burden for cross-border shipments, influencing lead times and inventory planning at hospitals, ambulatory surgical centers, and clinics. Clinicians and administrators are adapting by privileging products with stable supply histories and by engaging in multi-year procurement arrangements that emphasize transparency on origin and contingency planning. These collective adjustments underline the importance of supply chain resilience and collaborative contracting as defensive strategies in an era of trade uncertainty.
An integrated segmentation framework linking molecule properties, treatment pathways, patient cohorts, clinical indications, care settings, and distribution channels for targeted strategy
High-resolution segmentation is central to meaningful strategy development because therapeutic choices and procurement dynamics vary significantly across molecule, delivery approach, patient demographics, indication, end user, and distribution channel. The product mix is differentiated by molecule type-Dexamethasone, Hydrocortisone, Methylprednisolone, and Triamcinolone-each bringing distinct potency, solubility, and duration profiles that shape clinician preference and formulation strategy. Treatment type stratification captures clinical workflow differences among joint injections, soft tissue injections, and spinal injections; within joint injections, clinical practice diverges between large joint and small joint protocols, while soft tissue procedures further split into bursa injections, ligament injections, and tendon injections, and spinal approaches bifurcate into epidural and intrathecal pathways, each with unique safety, training, and device requirements.
Patient type segmentation recognizes differing safety considerations, dosing regimens, and consent processes across adult, geriatric, and pediatric cohorts, necessitating tailored labeling, educational materials, and post-procedure monitoring protocols. Therapeutic indication breakdowns-encompassing back pain, bursitis, osteoarthritis, rheumatoid arthritis, and tendonitis-highlight how clinical guidelines and expected outcomes vary; back pain itself is parsed into lower back pain, sciatica, and upper back pain, each demanding specific injection approaches and diagnostic clarity. End-user segmentation distinguishes ambulatory surgical centers, clinics, and hospitals, with hospitals further divided into general and specialty institutions, influencing procurement scale, formularies, and in-house compounding capabilities. Distribution channel considerations separate hospital pharmacies, online pharmacies, and retail pharmacies, with retail further split into chain and independent pharmacies, affecting access, dispensing protocols, and patient counseling. Synthesizing these segmentation dimensions enables targeted clinical evidence generation, differentiated marketing, and operational planning that align products with the distinct needs of clinicians, payers, and patients across care settings.
A regional analysis of clinical adoption, regulatory expectations, and procurement mechanics across the Americas, Europe Middle East Africa, and Asia Pacific markets
Regional dynamics substantially influence clinical practice patterns, regulatory requirements, and procurement mechanisms, demanding regionally informed strategies for product registration, distribution, and stakeholder engagement. The Americas present diverse payer landscapes and a strong outpatient procedural shift that favors ambulatory surgical centers and clinic-based administration of injections, with established reimbursement pathways that reward efficiency and documented outcomes. Regulatory and reimbursement variability across national and subnational jurisdictions requires tailored evidence dossiers and adaptive pricing approaches to accommodate divergent procurement rules and hospital formulary processes.
The Europe, Middle East & Africa region displays heterogeneity in clinical adoption and infrastructure; Western European markets emphasize rigorous health technology assessment and long-term outcomes data, while several markets in the Middle East and Africa are focused on access, supply chain reliability, and capacity building for procedural training. These differences necessitate bifurcated strategies that combine robust clinical data packages with targeted capacity development. The Asia-Pacific region is characterized by rapid procedural uptake in ambulatory settings, strong local manufacturing capabilities in select markets, and varying regulatory regimes that influence ingredient sourcing and device approvals. Across all regions, successful entrants align their regulatory submissions, distribution partnerships, and clinician engagement programs with local practice conventions, reimbursement models, and supply chain realities.
Competitive and operational insights revealing how manufacturers, device innovators, and distribution partners are positioning for clinical adoption and supply resilience
Competitive dynamics in the steroid injection space are defined by a mix of pharmaceutical manufacturers, device innovators, contract manufacturing organizations, and specialty distributors that prioritize clinical evidence, supply reliability, and integrated service offerings. Leading manufacturers focus on optimizing formulation portfolios to address differentiated clinician needs for potency, onset, and duration while investing in safety and administration training programs that enhance product uptake in ambulatory and hospital settings. Device and delivery system innovators are introducing solutions that simplify procedure workflow, improve dosing precision, and reduce procedural risk, which in turn influence purchasing preferences among high-volume clinics and surgical centers.
Contract manufacturing and packaging partners are increasingly important as companies seek to localize production and manage cost pressures introduced by trade policy shifts. Distribution and logistics partners that demonstrate strong cold chain management, responsive replenishment, and transparent origin documentation provide competitive advantages, particularly for large healthcare systems and specialty hospitals. Across the competitive spectrum, companies that couple compelling clinical data with robust educational outreach and supply chain transparency stand to secure preferred placement on institutional formularies and long-term procurement agreements. Strategic partnerships that align manufacturing agility with clinical validation efforts will be critical for sustaining access and adoption in diverse end-user environments.
Practical and prioritized strategic actions for manufacturers and stakeholders to strengthen evidence, secure supply chains, and accelerate clinical adoption across diverse care settings
Industry leaders should pursue a coordinated agenda that blends clinical evidence generation, supply chain resilience, and targeted commercialization to capitalize on shifts in care delivery and payer expectations. Prioritize investment in pragmatic studies and real-world evidence that demonstrate comparative effectiveness across molecule types and treatment pathways, ensuring that dossiers address clinician questions around duration of benefit, safety in geriatric and pediatric populations, and outcomes across specific indications such as osteoarthritis, rheumatoid arthritis, and differentiated back pain subtypes. Align these evidence efforts with educational programs tailored to large joint versus small joint procedures and to specialized spinal techniques, thereby reducing adoption friction and building clinician confidence.
Simultaneously, strengthen supplier diversification and consider regionalized manufacturing partnerships to mitigate tariff exposure and reduce lead-time variability for hospitals, ambulatory surgical centers, and clinics. Enhance distribution strategies by forming deep collaborations with hospital pharmacies and specialty distributors, as well as by optimizing online pharmacy channel policies to support appropriate dispensing while maintaining adherence to regulatory requirements. Finally, implement segmented commercial strategies that reflect differences in end-user procurement behavior and distribution channel dynamics; for example, offer bundled training and inventory management solutions for ambulatory surgical centers, while delivering streamlined formulary submission packages and long-term supply guarantees for specialty hospitals. These combined actions will improve market responsiveness, protect margins, and accelerate adoption in priority clinical segments.
A rigorous mixed-methods methodology that integrates clinical literature review, procurement analysis, and primary stakeholder interviews for validated strategic insights
The research methodology underpinning this executive summary combines multi-source evidence gathering, primary stakeholder engagement, and cross-validation to ensure robustness and actionable insight. The approach begins with a comprehensive review of peer-reviewed clinical literature, clinical practice guidelines, and regulatory documentation to establish baseline evidence on molecule characteristics, procedural protocols, and safety considerations. This foundation is augmented by analyses of procurement guidelines, hospital formularies, and publicly available procedural utilization data to identify variations in site-of-care practice patterns and distribution channel behavior.
Primary research includes structured interviews with clinicians across specialties that administer injections, procurement leads from ambulatory surgical centers and hospitals, and supply chain managers responsible for pharmacy operations. These qualitative inputs are synthesized with secondary datasets and validated through triangulation techniques to reconcile conflicting observations and to surface consistent trends. Segmentation mapping and regional analyses are informed by coded interview data and cross-checked against regulatory frameworks and published clinical guidance. Throughout, emphasis was placed on methodological transparency, reproducibility of thematic findings, and the practical applicability of recommendations to support decision making by clinical, commercial, and supply chain stakeholders.
A forward-looking synthesis highlighting strategic priorities and the practical convergence of clinical evidence, supply resilience, and targeted commercialization in steroid injections
In conclusion, the steroid injection landscape is at an inflection point where clinical practice, payer expectations, and supply chain realities converge to create both risk and opportunity. Stakeholders who invest in differentiated clinical evidence, ensure supply chain diversification in response to trade and regulatory shifts, and tailor commercialization to segmented clinical and distribution pathways will be best positioned to secure sustainable adoption. The segmentation framework spanning molecule type, treatment modality, patient cohort, therapeutic indication, end user, and distribution channel provides a practical lens through which to prioritize investments and to design targeted market access strategies.
Looking ahead, the combination of enhanced delivery technologies, a growing emphasis on real-world outcomes, and regionally varied regulatory environments will continue to shape clinical adoption and procurement decisions. Organizations that proactively align their clinical development, manufacturing footprint, and commercial execution with these structural trends will reduce execution risk and create pathways to differentiated market presence. The recommendations outlined here offer a roadmap for translating analytical insight into measurable operational and commercial actions that support better patient outcomes and stronger institutional partnerships.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid adoption of PD-1 and PD-L1 inhibitors in first-line gastric cancer treatment
- 5.2. Integration of molecular biomarker screening to personalize gastric cancer therapies
- 5.3. Increasing use of liquid biopsy for early detection and monitoring of tumor recurrence
- 5.4. Development of FGFR2 targeting agents for advanced gastric cancer patients with receptor amplification
- 5.5. Expansion of minimally invasive robotic surgery to improve postoperative outcomes in gastric cancer
- 5.6. Utilization of real-world evidence to optimize treatment sequencing in metastatic gastric cancer
- 5.7. Growth of combination immunotherapy and chemotherapy regimens in advanced stomach cancer management
- 5.8. Rising investment in AI-enabled endoscopic systems to enhance early gastric cancer diagnosis accuracy
- 5.9. Emergence of CAR-T cell therapies targeting Claudin 18.2 in refractory gastric tumors
- 5.10. Impact of evolving reimbursement policies on accessibility of novel gastric cancer treatments across markets
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Stomach Cancer Treatment Market, by Treatment Type
- 8.1. Chemotherapy
- 8.1.1. Fluorouracil-Based
- 8.1.2. Platinum-Based
- 8.1.3. Taxane-Based
- 8.2. Immunotherapy
- 8.3. Radiotherapy
- 8.3.1. Brachytherapy
- 8.3.2. External Beam
- 8.4. Surgery
- 8.4.1. Partial Gastrectomy
- 8.4.2. Total Gastrectomy
- 8.5. Targeted Therapy
- 9. Stomach Cancer Treatment Market, by Route Of Administration
- 9.1. Intravenous
- 9.2. Oral
- 10. Stomach Cancer Treatment Market, by Stage
- 10.1. Stage I
- 10.2. Stage Ii
- 10.3. Stage Iii
- 10.4. Stage Iv
- 11. Stomach Cancer Treatment Market, by Distribution Channel
- 11.1. Hospital Pharmacy
- 11.2. Online Pharmacy
- 11.3. Retail Pharmacy
- 12. Stomach Cancer Treatment Market, by End User
- 12.1. Homecare
- 12.2. Hospitals
- 12.3. Specialty Clinics
- 13. Stomach Cancer Treatment Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Stomach Cancer Treatment Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Stomach Cancer Treatment Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. AbbVie Inc.
- 16.3.2. Amgen Inc.
- 16.3.3. AstraZeneca PLC
- 16.3.4. Bayer AG
- 16.3.5. Bristol Myers Squibb Company
- 16.3.6. Celltrion Inc.
- 16.3.7. Daiichi Sankyo Company, Limited
- 16.3.8. Eisai Co., Ltd.
- 16.3.9. Eli Lilly and Company
- 16.3.10. F. Hoffmann-La Roche Ltd.
- 16.3.11. Johnson & Johnson
- 16.3.12. Merck & Co., Inc.
- 16.3.13. Novartis AG
- 16.3.14. Otsuka Pharmaceutical Co., Ltd.
- 16.3.15. Pfizer Inc.
- 16.3.16. Sanofi S.A.
- 16.3.17. Taiho Pharmaceutical Co., Ltd.
- 16.3.18. Takeda Pharmaceutical Company Limited
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
